{"transactions":[{"id":694319,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-08-06T20:13:19.000Z","date":"2026-08-04","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":30.48,"value":914400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $30.25 to $30.88. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":54645,"source":{"system":"sec-edgar","filing":"0001439222-26-000120","document":"wk-form4_1786047196.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000120/wk-form4_1786047196.xml","form_type":"4"}},{"id":711217,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":31000,"kind":"person","name":"Backstrom Jay T.","position":1,"cik":"0001796398","reported_name":"Backstrom Jay T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-07-10T16:18:00.000Z","date":"2026-07-08","kind":"exercise","planned":false,"acquired":false,"shares":1447,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on July 8, 2025. Beginning on July 8, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on July 8, 2025. Beginning on July 8, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":2894,"derivative":{"underlying":"Common stock","underlying_shares":1447},"source":{"system":"sec-edgar","filing":"0001439222-26-000112","document":"wk-form4_1783714678.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1796398/000143922226000112/wk-form4_1783714678.xml","form_type":"4"}},{"id":711216,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":31000,"kind":"person","name":"Backstrom Jay T.","position":1,"cik":"0001796398","reported_name":"Backstrom Jay T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2026-07-10T16:18:00.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":1447,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1447,"source":{"system":"sec-edgar","filing":"0001439222-26-000112","document":"wk-form4_1783714678.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796398/000143922226000112/wk-form4_1783714678.xml","form_type":"4"}},{"id":718398,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2026-07-02T20:03:16.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":8375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":8375},"source":{"system":"sec-edgar","filing":"0001439222-26-000110","document":"wk-form4_1783022592.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000110/wk-form4_1783022592.xml","form_type":"4"}},{"id":718397,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-07-02T20:03:16.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":4007,"price":37.56,"value":150502.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated July 1, 2023."}],"balance_after":84645,"source":{"system":"sec-edgar","filing":"0001439222-26-000110","document":"wk-form4_1783022592.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000110/wk-form4_1783022592.xml","form_type":"4"}},{"id":718396,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-07-02T20:03:16.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":8375,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":88652,"source":{"system":"sec-edgar","filing":"0001439222-26-000110","document":"wk-form4_1783022592.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000110/wk-form4_1783022592.xml","form_type":"4"}},{"id":729196,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2026-06-23T21:25:18.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":14950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027."}],"balance_after":14950,"derivative":{"exercise_price":34.16,"expiration_date":"2036-06-18","underlying":"Common stock","underlying_shares":14950},"source":{"system":"sec-edgar","filing":"0001439222-26-000107","document":"wk-form4_1782249916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922226000107/wk-form4_1782249916.xml","form_type":"4"}},{"id":729195,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:25:18.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":2927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2927,"derivative":{"underlying":"Common stock","underlying_shares":2927},"source":{"system":"sec-edgar","filing":"0001439222-26-000107","document":"wk-form4_1782249916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922226000107/wk-form4_1782249916.xml","form_type":"4"}},{"id":729194,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:25:18.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2816},"source":{"system":"sec-edgar","filing":"0001439222-26-000107","document":"wk-form4_1782249916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922226000107/wk-form4_1782249916.xml","form_type":"4"}},{"id":729193,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35999,"kind":"person","name":"Ballal Rahul D.","position":1,"cik":"0001805097","reported_name":"Ballal Rahul D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2026-06-23T21:25:18.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":true,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15230,"source":{"system":"sec-edgar","filing":"0001439222-26-000107","document":"wk-form4_1782249916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805097/000143922226000107/wk-form4_1782249916.xml","form_type":"4"}},{"id":729062,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35962,"kind":"person","name":"CAPELLO JEFFREY D","position":1,"cik":"0001224108","reported_name":"CAPELLO JEFFREY D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2026-06-23T21:24:38.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":14950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027."}],"balance_after":14950,"derivative":{"exercise_price":34.16,"expiration_date":"2036-06-18","underlying":"Common stock","underlying_shares":14950},"source":{"system":"sec-edgar","filing":"0001439222-26-000105","document":"wk-form4_1782249875.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000105/wk-form4_1782249875.xml","form_type":"4"}},{"id":729061,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35962,"kind":"person","name":"CAPELLO JEFFREY D","position":1,"cik":"0001224108","reported_name":"CAPELLO JEFFREY D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:24:38.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":2927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2927,"derivative":{"underlying":"Common stock","underlying_shares":2927},"source":{"system":"sec-edgar","filing":"0001439222-26-000105","document":"wk-form4_1782249875.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000105/wk-form4_1782249875.xml","form_type":"4"}},{"id":729060,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35962,"kind":"person","name":"CAPELLO JEFFREY D","position":1,"cik":"0001224108","reported_name":"CAPELLO JEFFREY D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:24:38.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2816},"source":{"system":"sec-edgar","filing":"0001439222-26-000105","document":"wk-form4_1782249875.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000105/wk-form4_1782249875.xml","form_type":"4"}},{"id":729059,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35962,"kind":"person","name":"CAPELLO JEFFREY D","position":1,"cik":"0001224108","reported_name":"CAPELLO JEFFREY D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2026-06-23T21:24:38.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":true,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10865,"source":{"system":"sec-edgar","filing":"0001439222-26-000105","document":"wk-form4_1782249875.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000105/wk-form4_1782249875.xml","form_type":"4"}},{"id":729058,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":13218,"kind":"person","name":"Foster-Cheek Kaye I","position":1,"cik":"0001312622","reported_name":"Foster-Cheek Kaye I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2026-06-23T21:23:55.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":14950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027."}],"balance_after":14950,"derivative":{"exercise_price":34.16,"expiration_date":"2036-06-18","underlying":"Common stock","underlying_shares":14950},"source":{"system":"sec-edgar","filing":"0001439222-26-000103","document":"wk-form4_1782249832.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000103/wk-form4_1782249832.xml","form_type":"4"}},{"id":729057,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":13218,"kind":"person","name":"Foster-Cheek Kaye I","position":1,"cik":"0001312622","reported_name":"Foster-Cheek Kaye I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:23:55.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":2927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2927,"derivative":{"underlying":"Common stock","underlying_shares":2927},"source":{"system":"sec-edgar","filing":"0001439222-26-000103","document":"wk-form4_1782249832.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000103/wk-form4_1782249832.xml","form_type":"4"}},{"id":729056,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":13218,"kind":"person","name":"Foster-Cheek Kaye I","position":1,"cik":"0001312622","reported_name":"Foster-Cheek Kaye I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:23:55.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2816},"source":{"system":"sec-edgar","filing":"0001439222-26-000103","document":"wk-form4_1782249832.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000103/wk-form4_1782249832.xml","form_type":"4"}},{"id":729055,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":13218,"kind":"person","name":"Foster-Cheek Kaye I","position":1,"cik":"0001312622","reported_name":"Foster-Cheek Kaye I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2026-06-23T21:23:55.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":true,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10284,"source":{"system":"sec-edgar","filing":"0001439222-26-000103","document":"wk-form4_1782249832.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000103/wk-form4_1782249832.xml","form_type":"4"}},{"id":729050,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35960,"kind":"person","name":"FOUSE JACQUALYN A","position":1,"cik":"0001405288","reported_name":"FOUSE JACQUALYN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2026-06-23T21:22:58.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":14950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027."}],"balance_after":14950,"derivative":{"exercise_price":34.16,"expiration_date":"2036-06-18","underlying":"Common stock","underlying_shares":14950},"source":{"system":"sec-edgar","filing":"0001439222-26-000101","document":"wk-form4_1782249776.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000101/wk-form4_1782249776.xml","form_type":"4"}},{"id":729049,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35960,"kind":"person","name":"FOUSE JACQUALYN A","position":1,"cik":"0001405288","reported_name":"FOUSE JACQUALYN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:22:58.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":2927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2927,"derivative":{"underlying":"Common stock","underlying_shares":2927},"source":{"system":"sec-edgar","filing":"0001439222-26-000101","document":"wk-form4_1782249776.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000101/wk-form4_1782249776.xml","form_type":"4"}},{"id":729048,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35960,"kind":"person","name":"FOUSE JACQUALYN A","position":1,"cik":"0001405288","reported_name":"FOUSE JACQUALYN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:22:58.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2816},"source":{"system":"sec-edgar","filing":"0001439222-26-000101","document":"wk-form4_1782249776.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000101/wk-form4_1782249776.xml","form_type":"4"}},{"id":729047,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35960,"kind":"person","name":"FOUSE JACQUALYN A","position":1,"cik":"0001405288","reported_name":"FOUSE JACQUALYN A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2026-06-23T21:22:58.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":true,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":154156,"source":{"system":"sec-edgar","filing":"0001439222-26-000101","document":"wk-form4_1782249776.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000101/wk-form4_1782249776.xml","form_type":"4"}},{"id":729054,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2026-06-23T21:21:59.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":14950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027."}],"balance_after":14950,"derivative":{"exercise_price":34.16,"expiration_date":"2036-06-18","underlying":"Common stock","underlying_shares":14950},"source":{"system":"sec-edgar","filing":"0001439222-26-000099","document":"wk-form4_1782249717.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000099/wk-form4_1782249717.xml","form_type":"4"}},{"id":729053,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:21:59.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":2927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2927,"derivative":{"underlying":"Common stock","underlying_shares":2927},"source":{"system":"sec-edgar","filing":"0001439222-26-000099","document":"wk-form4_1782249717.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000099/wk-form4_1782249717.xml","form_type":"4"}},{"id":729052,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:21:59.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2816},"source":{"system":"sec-edgar","filing":"0001439222-26-000099","document":"wk-form4_1782249717.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000099/wk-form4_1782249717.xml","form_type":"4"}},{"id":729051,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2026-06-23T21:21:59.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":true,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":19848,"source":{"system":"sec-edgar","filing":"0001439222-26-000099","document":"wk-form4_1782249717.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000099/wk-form4_1782249717.xml","form_type":"4"}},{"id":729217,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36004,"kind":"person","name":"Owen Adams Catherine","position":1,"cik":"0001816838","reported_name":"Owen Adams Catherine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2026-06-23T21:21:19.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":14950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027."}],"balance_after":14950,"derivative":{"exercise_price":34.16,"expiration_date":"2036-06-18","underlying":"Common stock","underlying_shares":14950},"source":{"system":"sec-edgar","filing":"0001439222-26-000097","document":"wk-form4_1782249676.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1816838/000143922226000097/wk-form4_1782249676.xml","form_type":"4"}},{"id":729216,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36004,"kind":"person","name":"Owen Adams Catherine","position":1,"cik":"0001816838","reported_name":"Owen Adams Catherine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:21:19.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":2927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2927,"derivative":{"underlying":"Common stock","underlying_shares":2927},"source":{"system":"sec-edgar","filing":"0001439222-26-000097","document":"wk-form4_1782249676.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816838/000143922226000097/wk-form4_1782249676.xml","form_type":"4"}},{"id":729215,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36004,"kind":"person","name":"Owen Adams Catherine","position":1,"cik":"0001816838","reported_name":"Owen Adams Catherine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:21:19.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2816},"source":{"system":"sec-edgar","filing":"0001439222-26-000097","document":"wk-form4_1782249676.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816838/000143922226000097/wk-form4_1782249676.xml","form_type":"4"}},{"id":729214,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36004,"kind":"person","name":"Owen Adams Catherine","position":1,"cik":"0001816838","reported_name":"Owen Adams Catherine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2026-06-23T21:21:19.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":true,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10865,"source":{"system":"sec-edgar","filing":"0001439222-26-000097","document":"wk-form4_1782249676.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816838/000143922226000097/wk-form4_1782249676.xml","form_type":"4"}},{"id":729046,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2026-06-23T21:20:42.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":14950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027."}],"balance_after":14950,"derivative":{"exercise_price":34.16,"expiration_date":"2036-06-18","underlying":"Common stock","underlying_shares":14950},"source":{"system":"sec-edgar","filing":"0001439222-26-000095","document":"wk-form4_1782249639.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000095/wk-form4_1782249639.xml","form_type":"4"}},{"id":729045,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:20:42.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":2927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2927,"derivative":{"underlying":"Common stock","underlying_shares":2927},"source":{"system":"sec-edgar","filing":"0001439222-26-000095","document":"wk-form4_1782249639.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000095/wk-form4_1782249639.xml","form_type":"4"}},{"id":729044,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:20:42.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2816},"source":{"system":"sec-edgar","filing":"0001439222-26-000095","document":"wk-form4_1782249639.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000095/wk-form4_1782249639.xml","form_type":"4"}},{"id":729043,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2026-06-23T21:20:42.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":true,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20419,"source":{"system":"sec-edgar","filing":"0001439222-26-000095","document":"wk-form4_1782249639.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000095/wk-form4_1782249639.xml","form_type":"4"}},{"id":729042,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35382,"kind":"person","name":"Smith Cynthia","position":1,"cik":"0001609480","reported_name":"Smith Cynthia","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2026-06-23T21:19:33.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":14950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027."}],"balance_after":14950,"derivative":{"exercise_price":34.16,"expiration_date":"2036-06-18","underlying":"Common stock","underlying_shares":14950},"source":{"system":"sec-edgar","filing":"0001439222-26-000093","document":"wk-form4_1782249570.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000093/wk-form4_1782249570.xml","form_type":"4"}},{"id":729041,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35382,"kind":"person","name":"Smith Cynthia","position":1,"cik":"0001609480","reported_name":"Smith Cynthia","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:19:33.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":2927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2927,"derivative":{"underlying":"Common stock","underlying_shares":2927},"source":{"system":"sec-edgar","filing":"0001439222-26-000093","document":"wk-form4_1782249570.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000093/wk-form4_1782249570.xml","form_type":"4"}},{"id":729040,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35382,"kind":"person","name":"Smith Cynthia","position":1,"cik":"0001609480","reported_name":"Smith Cynthia","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:19:33.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2816},"source":{"system":"sec-edgar","filing":"0001439222-26-000093","document":"wk-form4_1782249570.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000093/wk-form4_1782249570.xml","form_type":"4"}},{"id":729039,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35382,"kind":"person","name":"Smith Cynthia","position":1,"cik":"0001609480","reported_name":"Smith Cynthia","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2026-06-23T21:19:33.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":true,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15230,"source":{"system":"sec-edgar","filing":"0001439222-26-000093","document":"wk-form4_1782249570.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000093/wk-form4_1782249570.xml","form_type":"4"}},{"id":729036,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35957,"kind":"person","name":"Viswanadhan Krishnan","position":1,"cik":"0001999913","reported_name":"Viswanadhan Krishnan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy and Operations"}}],"security":"Restricted stock units","published_at":"2026-06-23T21:18:32.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 5, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 5, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":3000,"derivative":{"underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001439222-26-000091","document":"wk-form4_1782249510.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000091/wk-form4_1782249510.xml","form_type":"4"}},{"id":729035,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35957,"kind":"person","name":"Viswanadhan Krishnan","position":1,"cik":"0001999913","reported_name":"Viswanadhan Krishnan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy and Operations"}}],"security":"Performance share units","published_at":"2026-06-23T21:18:32.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 5, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 5, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":9000,"derivative":{"underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001439222-26-000091","document":"wk-form4_1782249510.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000091/wk-form4_1782249510.xml","form_type":"4"}},{"id":729038,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2026-06-23T21:17:39.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":39000,"derivative":{"underlying":"Common stock","underlying_shares":39000},"source":{"system":"sec-edgar","filing":"0001439222-26-000089","document":"wk-form4_1782249456.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000089/wk-form4_1782249456.xml","form_type":"4"}},{"id":729037,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance share units","published_at":"2026-06-23T21:17:39.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":39000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":39000,"derivative":{"underlying":"Common stock","underlying_shares":39000},"source":{"system":"sec-edgar","filing":"0001439222-26-000089","document":"wk-form4_1782249456.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000089/wk-form4_1782249456.xml","form_type":"4"}},{"id":729034,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35956,"kind":"person","name":"Burns James William","position":1,"cik":"0001900772","reported_name":"Burns James William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted stock units","published_at":"2026-06-23T21:16:41.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting  of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026.  The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting  of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026.  The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":3000,"derivative":{"underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001439222-26-000087","document":"wk-form4_1782249398.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000087/wk-form4_1782249398.xml","form_type":"4"}},{"id":729033,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35956,"kind":"person","name":"Burns James William","position":1,"cik":"0001900772","reported_name":"Burns James William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Performance share units","published_at":"2026-06-23T21:16:41.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting  of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026.  The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting  of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026.  The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":9000,"derivative":{"underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001439222-26-000087","document":"wk-form4_1782249398.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000087/wk-form4_1782249398.xml","form_type":"4"}},{"id":729278,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2026-06-23T21:15:51.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":3000,"derivative":{"underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001439222-26-000085","document":"wk-form4_1782249348.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000085/wk-form4_1782249348.xml","form_type":"4"}},{"id":729277,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance share units","published_at":"2026-06-23T21:15:51.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":9000,"derivative":{"underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001439222-26-000085","document":"wk-form4_1782249348.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000085/wk-form4_1782249348.xml","form_type":"4"}},{"id":729030,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted stock units","published_at":"2026-06-23T21:14:03.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":3000,"derivative":{"underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001439222-26-000083","document":"wk-form4_1782249240.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000083/wk-form4_1782249240.xml","form_type":"4"}},{"id":729029,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance share units","published_at":"2026-06-23T21:14:03.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":9000,"derivative":{"underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001439222-26-000083","document":"wk-form4_1782249240.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000083/wk-form4_1782249240.xml","form_type":"4"}},{"id":729309,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted stock units","published_at":"2026-06-23T21:13:19.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":3000,"derivative":{"underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001439222-26-000081","document":"wk-form4_1782249197.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000081/wk-form4_1782249197.xml","form_type":"4"}},{"id":729308,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Performance share units","published_at":"2026-06-23T21:13:19.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Performance stock units were granted on March 1, 2025, and provide for the vesting of underlying shares upon the achievement of three specified clinical and research milestones established by the compensation & people committee, or board of directors, as applicable. The performance criteria for the specified research milestone was determined by the compensation & people committee to be met as of June 18, 2026. The shares related to such milestone will vest on December 31, 2027, subject to the recipient's continued service."}],"balance_after":9000,"derivative":{"underlying":"Common stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001439222-26-000081","document":"wk-form4_1782249197.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000081/wk-form4_1782249197.xml","form_type":"4"}},{"id":729187,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":31000,"kind":"person","name":"Backstrom Jay T.","position":1,"cik":"0001796398","reported_name":"Backstrom Jay T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2026-06-23T21:12:22.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":14950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027."}],"balance_after":14950,"derivative":{"exercise_price":34.16,"expiration_date":"2036-06-18","underlying":"Common stock","underlying_shares":14950},"source":{"system":"sec-edgar","filing":"0001439222-26-000079","document":"wk-form4_1782249139.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1796398/000143922226000079/wk-form4_1782249139.xml","form_type":"4"}},{"id":729186,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":31000,"kind":"person","name":"Backstrom Jay T.","position":1,"cik":"0001796398","reported_name":"Backstrom Jay T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:12:22.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":2927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2927,"derivative":{"underlying":"Common stock","underlying_shares":2927},"source":{"system":"sec-edgar","filing":"0001439222-26-000079","document":"wk-form4_1782249139.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796398/000143922226000079/wk-form4_1782249139.xml","form_type":"4"}},{"id":736333,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36004,"kind":"person","name":"Owen Adams Catherine","position":1,"cik":"0001816838","reported_name":"Owen Adams Catherine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-16T20:09:44.000Z","date":"2026-06-13","kind":"exercise","planned":false,"acquired":false,"shares":1976,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 13, 2023. Beginning on June 13, 2024, the shares underlying the stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 13, 2023. Beginning on June 13, 2024, the shares underlying the stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":1976},"source":{"system":"sec-edgar","filing":"0001439222-26-000077","document":"wk-form4_1781640580.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816838/000143922226000077/wk-form4_1781640580.xml","form_type":"4"}},{"id":736332,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36004,"kind":"person","name":"Owen Adams Catherine","position":1,"cik":"0001816838","reported_name":"Owen Adams Catherine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2026-06-16T20:09:44.000Z","date":"2026-06-13","kind":"exercise","planned":false,"acquired":true,"shares":1976,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8049,"source":{"system":"sec-edgar","filing":"0001439222-26-000077","document":"wk-form4_1781640580.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816838/000143922226000077/wk-form4_1781640580.xml","form_type":"4"}},{"id":736076,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35962,"kind":"person","name":"CAPELLO JEFFREY D","position":1,"cik":"0001224108","reported_name":"CAPELLO JEFFREY D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-16T20:06:47.000Z","date":"2026-06-13","kind":"exercise","planned":false,"acquired":false,"shares":1976,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 13, 2023. Beginning on June 13, 2024, the shares underlying the stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 13, 2023. Beginning on June 13, 2024, the shares underlying the stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":1976},"source":{"system":"sec-edgar","filing":"0001439222-26-000075","document":"wk-form4_1781640401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000075/wk-form4_1781640401.xml","form_type":"4"}},{"id":736075,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35962,"kind":"person","name":"CAPELLO JEFFREY D","position":1,"cik":"0001224108","reported_name":"CAPELLO JEFFREY D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2026-06-16T20:06:47.000Z","date":"2026-06-13","kind":"exercise","planned":false,"acquired":true,"shares":1976,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8049,"source":{"system":"sec-edgar","filing":"0001439222-26-000075","document":"wk-form4_1781640401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000075/wk-form4_1781640401.xml","form_type":"4"}},{"id":814402,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35956,"kind":"person","name":"Burns James William","position":1,"cik":"0001900772","reported_name":"Burns James William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Performance share units","published_at":"2026-04-06T20:11:49.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":8500,"derivative":{"underlying":"Common stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001439222-26-000067","document":"wk-form4_1775506306.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000067/wk-form4_1775506306.xml","form_type":"4"}},{"id":814401,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35956,"kind":"person","name":"Burns James William","position":1,"cik":"0001900772","reported_name":"Burns James William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:11:49.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":3280,"price":34.71,"value":113848.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2024."}],"balance_after":49306,"source":{"system":"sec-edgar","filing":"0001439222-26-000067","document":"wk-form4_1775506306.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000067/wk-form4_1775506306.xml","form_type":"4"}},{"id":814400,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35956,"kind":"person","name":"Burns James William","position":1,"cik":"0001900772","reported_name":"Burns James William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:11:49.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":52586,"source":{"system":"sec-edgar","filing":"0001439222-26-000067","document":"wk-form4_1775506306.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000067/wk-form4_1775506306.xml","form_type":"4"}},{"id":814541,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance share units","published_at":"2026-04-06T20:10:02.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":8500,"derivative":{"underlying":"Common stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001439222-26-000065","document":"wk-form4_1775506198.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000065/wk-form4_1775506198.xml","form_type":"4"}},{"id":814540,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:10:02.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":2940,"price":34.71,"value":102047.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2024."}],"balance_after":80277,"source":{"system":"sec-edgar","filing":"0001439222-26-000065","document":"wk-form4_1775506198.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000065/wk-form4_1775506198.xml","form_type":"4"}},{"id":814539,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":25902,"kind":"person","name":"Gheuens Sarah","position":1,"cik":"0001881190","reported_name":"Gheuens Sarah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:10:02.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 311 shares purchased through the Company's employee stock purchase plan."}],"balance_after":83217,"source":{"system":"sec-edgar","filing":"0001439222-26-000065","document":"wk-form4_1775506198.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881190/000143922226000065/wk-form4_1775506198.xml","form_type":"4"}},{"id":814399,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance share units","published_at":"2026-04-06T20:08:56.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":8500,"derivative":{"underlying":"Common stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001439222-26-000063","document":"wk-form4_1775506133.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000063/wk-form4_1775506133.xml","form_type":"4"}},{"id":814398,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:08:56.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":3141,"price":34.71,"value":109024.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2024."}],"balance_after":54998,"source":{"system":"sec-edgar","filing":"0001439222-26-000063","document":"wk-form4_1775506133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000063/wk-form4_1775506133.xml","form_type":"4"}},{"id":814397,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35955,"kind":"person","name":"Jones Cecilia","position":1,"cik":"0001840056","reported_name":"Jones Cecilia","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:08:56.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 311 shares purchased through the Company's employee stock purchase plan."}],"balance_after":58139,"source":{"system":"sec-edgar","filing":"0001439222-26-000063","document":"wk-form4_1775506133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000063/wk-form4_1775506133.xml","form_type":"4"}},{"id":814556,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Performance share units","published_at":"2026-04-06T20:07:20.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs were granted on March 1, 2024. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":8500,"derivative":{"underlying":"Common stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001439222-26-000061","document":"wk-form4_1775506037.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000061/wk-form4_1775506037.xml","form_type":"4"}},{"id":814555,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:07:20.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":3262,"price":34.71,"value":113224.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2024."}],"balance_after":46829,"source":{"system":"sec-edgar","filing":"0001439222-26-000061","document":"wk-form4_1775506037.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000061/wk-form4_1775506037.xml","form_type":"4"}},{"id":814554,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":36035,"kind":"person","name":"Milanova Tsveta","position":1,"cik":"0001957180","reported_name":"Milanova Tsveta","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:07:20.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50091,"source":{"system":"sec-edgar","filing":"0001439222-26-000061","document":"wk-form4_1775506037.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1957180/000143922226000061/wk-form4_1775506037.xml","form_type":"4"}},{"id":814396,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35957,"kind":"person","name":"Viswanadhan Krishnan","position":1,"cik":"0001999913","reported_name":"Viswanadhan Krishnan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp Dev & Strategy"}}],"security":"Performance share units","published_at":"2026-04-06T20:05:31.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":false,"shares":8100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs were granted on March 5, 2025. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs were granted on March 5, 2025. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":8100,"derivative":{"underlying":"Common stock","underlying_shares":8100},"source":{"system":"sec-edgar","filing":"0001439222-26-000059","document":"wk-form4_1775505928.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000059/wk-form4_1775505928.xml","form_type":"4"}},{"id":814395,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35957,"kind":"person","name":"Viswanadhan Krishnan","position":1,"cik":"0001999913","reported_name":"Viswanadhan Krishnan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp Dev & Strategy"}}],"security":"Common stock","published_at":"2026-04-06T20:05:31.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":2959,"price":34.71,"value":102706.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 5, 2025."}],"balance_after":10282,"source":{"system":"sec-edgar","filing":"0001439222-26-000059","document":"wk-form4_1775505928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000059/wk-form4_1775505928.xml","form_type":"4"}},{"id":814394,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35957,"kind":"person","name":"Viswanadhan Krishnan","position":1,"cik":"0001999913","reported_name":"Viswanadhan Krishnan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp Dev & Strategy"}}],"security":"Common stock","published_at":"2026-04-06T20:05:31.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":true,"shares":8100,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":13241,"source":{"system":"sec-edgar","filing":"0001439222-26-000059","document":"wk-form4_1775505928.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000059/wk-form4_1775505928.xml","form_type":"4"}},{"id":814393,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance share units","published_at":"2026-04-06T20:04:26.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":false,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The PSUs were granted on March 1, 2024. The PSUs vest as to 25% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 75% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 25% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The PSUs were granted on March 1, 2024. The PSUs vest as to 25% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 75% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 25% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":40500,"derivative":{"underlying":"Common stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001439222-26-000057","document":"wk-form4_1775505863.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000057/wk-form4_1775505863.xml","form_type":"4"}},{"id":814392,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance share units","published_at":"2026-04-06T20:04:26.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":false,"shares":25528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining underlying shares upon the achievement of other clinical and regulatory milestones. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The PSUs were granted on August 8, 2022. The PSUs vest as to 15% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining underlying shares upon the achievement of other clinical and regulatory milestones. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 15% of the underlying shares of common stock. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":25528},"source":{"system":"sec-edgar","filing":"0001439222-26-000057","document":"wk-form4_1775505863.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000057/wk-form4_1775505863.xml","form_type":"4"}},{"id":814391,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:04:26.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":6596,"price":34.71,"value":228947.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2024."}],"balance_after":184508,"source":{"system":"sec-edgar","filing":"0001439222-26-000057","document":"wk-form4_1775505863.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000057/wk-form4_1775505863.xml","form_type":"4"}},{"id":814390,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:04:26.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":191104,"source":{"system":"sec-edgar","filing":"0001439222-26-000057","document":"wk-form4_1775505863.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000057/wk-form4_1775505863.xml","form_type":"4"}},{"id":814389,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:04:26.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":12472,"price":34.71,"value":432903.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated August 8, 2022."}],"balance_after":177604,"source":{"system":"sec-edgar","filing":"0001439222-26-000057","document":"wk-form4_1775505863.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000057/wk-form4_1775505863.xml","form_type":"4"}},{"id":814388,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-04-06T20:04:26.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":true,"shares":25528,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":190076,"source":{"system":"sec-edgar","filing":"0001439222-26-000057","document":"wk-form4_1775505863.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000057/wk-form4_1775505863.xml","form_type":"4"}},{"id":853407,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35957,"kind":"person","name":"Viswanadhan Krishnan","position":1,"cik":"0001999913","reported_name":"Viswanadhan Krishnan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp Dev & Strategy"}}],"security":"Restricted stock units","published_at":"2026-03-09T20:12:11.000Z","date":"2026-03-05","kind":"exercise","planned":true,"acquired":false,"shares":8100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on March 5, 2025. Beginning on March 5, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on March 5, 2025. Beginning on March 5, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":16200,"derivative":{"underlying":"Common stock","underlying_shares":8100},"source":{"system":"sec-edgar","filing":"0001439222-26-000049","document":"wk-form4_1773087128.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000049/wk-form4_1773087128.xml","form_type":"4"}},{"id":853406,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35957,"kind":"person","name":"Viswanadhan Krishnan","position":1,"cik":"0001999913","reported_name":"Viswanadhan Krishnan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp Dev & Strategy"}}],"security":"Common stock","published_at":"2026-03-09T20:12:11.000Z","date":"2026-03-05","kind":"sale","planned":true,"acquired":false,"shares":2959,"price":27.8,"value":82260.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 5, 2025."}],"balance_after":5141,"source":{"system":"sec-edgar","filing":"0001439222-26-000049","document":"wk-form4_1773087128.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000049/wk-form4_1773087128.xml","form_type":"4"}},{"id":853405,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35957,"kind":"person","name":"Viswanadhan Krishnan","position":1,"cik":"0001999913","reported_name":"Viswanadhan Krishnan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Corp Dev & Strategy"}}],"security":"Common stock","published_at":"2026-03-09T20:12:11.000Z","date":"2026-03-05","kind":"exercise","planned":true,"acquired":true,"shares":8100,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8100,"source":{"system":"sec-edgar","filing":"0001439222-26-000049","document":"wk-form4_1773087128.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000049/wk-form4_1773087128.xml","form_type":"4"}},{"id":858210,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":62539,"kind":"person","name":"Washburn Theodore James Jr.","position":1,"cik":"0001874199","reported_name":"Washburn Theodore James Jr.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common stock","published_at":"2026-03-05T21:08:15.000Z","date":"2026-03-03","kind":"sale","planned":false,"acquired":false,"shares":5272,"price":28.88,"value":152255.36,"ownership":{"direct":true},"balance_after":868,"source":{"system":"sec-edgar","filing":"0001439222-26-000046","document":"wk-form4_1772744891.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000046/wk-form4_1772744891.xml","form_type":"4"}},{"id":866588,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":26000,"derivative":{"underlying":"Common stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866587,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":18000,"derivative":{"underlying":"Common stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866586,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866585,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock options (right to buy)","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-01","kind":"grant","planned":true,"acquired":true,"shares":174000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":174000,"derivative":{"exercise_price":30.23,"expiration_date":"2036-03-01","underlying":"Common stock","underlying_shares":174000},"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866584,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-01","kind":"grant","planned":true,"acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":48000,"derivative":{"underlying":"Common stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866583,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":5918,"price":28.96,"value":171385.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2025."}],"balance_after":164548,"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866582,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":170466,"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866581,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":8267,"price":28.96,"value":239412.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024."}],"balance_after":157466,"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866580,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":165733,"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866579,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":3870,"price":28.96,"value":112075.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023."}],"balance_after":147733,"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866578,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35958,"kind":"person","name":"Goff Brian","position":1,"cik":"0001546216","reported_name":"Goff Brian","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:17:52.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":151603,"source":{"system":"sec-edgar","filing":"0001439222-26-000044","document":"wk-form4_1772572669.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000044/wk-form4_1772572669.xml","form_type":"4"}},{"id":866563,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35956,"kind":"person","name":"Burns James William","position":1,"cik":"0001900772","reported_name":"Burns James William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:17:08.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":3920,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The restricted stock units were granted on  March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The restricted stock units were granted on  March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":7839,"derivative":{"underlying":"Common stock","underlying_shares":3920},"source":{"system":"sec-edgar","filing":"0001439222-26-000042","document":"wk-form4_1772572612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000042/wk-form4_1772572612.xml","form_type":"4"}},{"id":866562,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35956,"kind":"person","name":"Burns James William","position":1,"cik":"0001900772","reported_name":"Burns James William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:17:08.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The restricted stock units were granted on  March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The restricted stock units were granted on  March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":8000,"derivative":{"underlying":"Common stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001439222-26-000042","document":"wk-form4_1772572612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000042/wk-form4_1772572612.xml","form_type":"4"}},{"id":866561,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35956,"kind":"person","name":"Burns James William","position":1,"cik":"0001900772","reported_name":"Burns James William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:17:08.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":5666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":5667,"derivative":{"underlying":"Common stock","underlying_shares":5666},"source":{"system":"sec-edgar","filing":"0001439222-26-000042","document":"wk-form4_1772572612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000042/wk-form4_1772572612.xml","form_type":"4"}},{"id":866560,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35956,"kind":"person","name":"Burns James William","position":1,"cik":"0001900772","reported_name":"Burns James William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:17:08.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001439222-26-000042","document":"wk-form4_1772572612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000042/wk-form4_1772572612.xml","form_type":"4"}},{"id":866559,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35956,"kind":"person","name":"Burns James William","position":1,"cik":"0001900772","reported_name":"Burns James William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock options (right to buy)","published_at":"2026-03-03T21:17:08.000Z","date":"2026-03-01","kind":"grant","planned":true,"acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":52000,"derivative":{"exercise_price":30.23,"expiration_date":"2036-03-01","underlying":"Common stock","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0001439222-26-000042","document":"wk-form4_1772572612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000042/wk-form4_1772572612.xml","form_type":"4"}},{"id":866558,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35956,"kind":"person","name":"Burns James William","position":1,"cik":"0001900772","reported_name":"Burns James William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted stock units","published_at":"2026-03-03T21:17:08.000Z","date":"2026-03-01","kind":"grant","planned":true,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":14000,"derivative":{"underlying":"Common stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001439222-26-000042","document":"wk-form4_1772572612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000042/wk-form4_1772572612.xml","form_type":"4"}},{"id":866557,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35956,"kind":"person","name":"Burns James William","position":1,"cik":"0001900772","reported_name":"Burns James William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:17:08.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":1163,"price":28.96,"value":33680.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2025."}],"balance_after":44086,"source":{"system":"sec-edgar","filing":"0001439222-26-000042","document":"wk-form4_1772572612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000042/wk-form4_1772572612.xml","form_type":"4"}},{"id":866556,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35956,"kind":"person","name":"Burns James William","position":1,"cik":"0001900772","reported_name":"Burns James William","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common stock","published_at":"2026-03-03T21:17:08.000Z","date":"2026-03-02","kind":"exercise","planned":true,"acquired":true,"shares":3920,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":45249,"source":{"system":"sec-edgar","filing":"0001439222-26-000042","document":"wk-form4_1772572612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000042/wk-form4_1772572612.xml","form_type":"4"}}],"next_cursor":"2026-03-03T21:17:08.000000Z,866556"}